APOLLO THERAPEUTICS

Serial Number 90798637
Registration 7172183
700

Registration Progress

Application Filed
Jun 28, 2021
Under Examination
Jun 6, 2023
Approved for Publication
Apr 11, 2023
Published for Opposition
Apr 11, 2023
Registered
Sep 26, 2023

Trademark Image

APOLLO THERAPEUTICS

Basic Information

Serial Number
90798637
Registration Number
7172183
Filing Date
June 28, 2021
Registration Date
September 26, 2023
Published for Opposition
April 11, 2023
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Sep 26, 2023
Registration
Registered
Classes
005 035 036 041
+2 more

Rights Holder

Apollo Therapeutics LLP

99
Address
52 Princes Gate, Exhibition Road
London SW72PG
GB

Ownership History

Apollo Therapeutics LLP

Original Applicant
99
London GB

Apollo Therapeutics LLP

Owner at Publication
99
London GB

Apollo Therapeutics LLP

Original Registrant
99
London GB

Legal Representation

Attorney
Benjamin Charkow

USPTO Deadlines

Next Deadline
1518 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2023-09-26)
Due Date
September 26, 2029
Grace Period Ends
March 26, 2030
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

38 events
Date Code Type Description Documents
Sep 26, 2023 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Sep 26, 2023 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Aug 21, 2023 DP1B I 1(B) BASIS DELETED; PROCEED TO REGISTRATION Loading...
Aug 21, 2023 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Jul 10, 2023 IUCN S NOTICE OF ALLOWANCE CANCELLED Loading...
Jul 10, 2023 D1BR I TEAS DELETE 1(B) BASIS RECEIVED Loading...
Jun 6, 2023 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Apr 11, 2023 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Apr 11, 2023 PUBO A PUBLISHED FOR OPPOSITION Loading...
Mar 22, 2023 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Mar 3, 2023 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Mar 1, 2023 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Mar 1, 2023 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Mar 1, 2023 GNEA O EXAMINERS AMENDMENT E-MAILED Loading...
Mar 1, 2023 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Feb 21, 2023 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Feb 21, 2023 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Feb 21, 2023 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jan 6, 2023 GNRT O NON-FINAL ACTION E-MAILED Loading...
Jan 6, 2023 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jan 6, 2023 CNRT R NON-FINAL ACTION WRITTEN Loading...
Nov 10, 2022 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Nov 9, 2022 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Nov 9, 2022 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Aug 30, 2022 DOCK D ASSIGNED TO EXAMINER Loading...
Jun 7, 2022 EWAF I TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS Loading...
Jun 7, 2022 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Jun 7, 2022 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Jun 7, 2022 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Jun 2, 2022 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jun 2, 2022 GNRT F NON-FINAL ACTION E-MAILED Loading...
Jun 2, 2022 CNRT R NON-FINAL ACTION WRITTEN Loading...
Mar 18, 2022 DOCK D ASSIGNED TO EXAMINER Loading...
Sep 10, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Aug 6, 2021 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Aug 6, 2021 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Aug 6, 2021 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Jul 1, 2021 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Therapeutic pharmaceuticals for the treatment of cardiovascular diseases, blood disorders, respiratory diseases, asthma, central nervous system disorders, cancer and tumors, diseases and disorders of the autoimmune system, allergies, renal transplant, hypertension, chronic kidney disease, and metabolic diseases; pharmaceutical preparations, namely biologics, biosimilars, small molecules, gene-engineered cell therapy in the nature of cells for medical use, namely autologous gene-engineered cells; medical preparations for the treatment of cardiovascular diseases, blood disorders, respiratory diseases, asthma, central nervous system disorders, cancer and tumors, diseases and disorders of the autoimmune system, allergies, renal transplant, hypertension, chronic kidney disease, and metabolic diseases
Class 035
Collection of data and management of data for business purposes in connection with clinical research, testing, trial and development of pharmaceuticals, therapeutics and medical devices; computerized database management and data processing services in the field of medical, pharmaceutical and therapeutic treatment
Class 036
Financial sponsorship in the form of providing financial resources to non-hospital partnerships, associations and companies, to aid in the research, development, production, import, export, retail, wholesale, promotion, commercial distribution and commercialisation of pharmaceutical, therapeutic and medicinal products and preparations
Class 041
Education services, namely, providing instruction in the field of pharmaceutical and therapeutic medical education; arranging and conducting of conferences, congresses, courses, in particular in the fields of medicine and pharmaceuticals; publishing services, namely, the publication of periodicals, books, magazines, and articles in the field of medicine, pharmaceuticals, and therapeutics; publication of periodicals, books, magazines, articles, in particular in the fields of medicine, pharmaceuticals and therapeutics
Class 042
Scientific, medical and pharmaceutical research and development services; clinical research in the field of the use of biologics, biosimilars, small molecules, gene-engineered cell therapy and vaccines for the treatment of cardiovascular diseases, blood disorders, respiratory diseases, asthma, central nervous system disorders, cancer and tumors, diseases and disorders of the autoimmune system, allergies, renal transplant, hypertension, chronic kidney disease, and metabolic diseases; pharmaceutical drug development services; scientific investigations for medical purposes; medical laboratory services; laboratory research services related to pharmaceuticals; advisory services relating to medical and pharmaceutical science research in the field of the use of biologics, biosimilars, small molecules, gene-engineered cell therapy and vaccines for the treatment of cardiovascular diseases, blood disorders, respiratory diseases, asthma, central nervous system disorders, cancer and tumors, diseases and disorders of the autoimmune system, allergies, renal transplant, hypertension, chronic kidney disease, and metabolic diseases; research and development of pharmaceutical preparations
Class 044
Non-emergency and non-clinical medical and pharmaceutical consulting services related to the use of pharmaceutical preparations, namely biologics, biosimilars, small molecules, gene-engineered cell therapy and vaccines; non-emergency medical analysis services for diagnostic and treatment purposes related to the use of pharmaceutical preparations, namely biologics, biosimilars, small molecules, gene-engineered cell therapy and vaccines, provided by medical laboratories; medical analysis and examination services related to the treatment of cardiovascular diseases, blood disorders, respiratory diseases, asthma, central nervous system disorders, cancer and tumors, diseases and disorders of the autoimmune system, allergies, renal transplant, hypertension, chronic kidney disease, and metabolic diseases, provided by medical laboratories; medical treatment of cardiovascular diseases, blood disorders, respiratory diseases, asthma, central nervous system disorders, cancer and tumors, diseases and disorders of the autoimmune system, allergies, renal transplant, hypertension, chronic kidney disease, and metabolic diseases; advisory services relating to medical and pharmaceutical science, namely, medical advisory services and pharmaceutical advisory services in the field of the use of biologics, biosimilars, small molecules, gene-engineered cell therapy and vaccines for the treatment of cardiovascular diseases, blood disorders, respiratory diseases, asthma, central nervous system disorders, cancer and tumors, diseases and disorders of the autoimmune system, allergies, renal transplant, hypertension, chronic kidney disease, and metabolic diseases

Classification

International Classes
005 035 036 041 042 044

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"THERAPEUTICS"